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Heat shock proteins (HSPs), known as molecular chaperone to assist protein folding, have recently become a 
research focus in Parkinson’s disease (PD) because the pathogenesis of this disease is highlighted by the 
intracellular protein misfolding and inclusion body formation. The present review will focus on the functions of 
different HSPs and their protective roles in PD. It is postulated that HSPs may serve as protein folding 
machinery and work together with ubiquitin-proteasome system (UPS) to assist in decomposing aberrant 
proteins. Failure of UPS is thought to play a key role in the pathogenesis of PD. In addition, HSPs may possess 
anti-apoptotic effects and keep the homeostasis of dopaminergic neurons against stress conditions. The critical 
role of HSPs and recent discovery of some novel HSPs inducers suggest that HSPs may be potential therapeutic 
targets for PD and other neurodegenerative disorders. 
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1.  Introduction of HSPs 
In the eukaryotic cell, heat shock proteins (HSPs) 
provide an intrinsic mechanism to defend the cell 
against external diverse physiological stress that may 
initiate a cascade of events affecting cell structure and 
function. The high conservation of HSPs throughout 
the evolution suggests that these proteins may have a 
vital role in protecting cells from injury. HSPs are 
composed of different classes of proteins according to 
their molecular weight, which include 
high-molecular-mass HSPs (≥100kD), HSP90 (81 to 
99kD), HSP70 (65 to 80kD), HSP60 (55 to 64kD), 
HSP40 (35 to 54kD) and small HSPs (≤34kD) [1]. 
Different classes of HSPs play a diversity role in 
governing proper protein assembly, folding, and 
translocation [1, 2]. Regulation of these HSPs 
synthesis creates a unique defense system to maintain 
cellular protein homeostasis and to ensure cell 
survival [2].  
The current understanding of HSPs’ function is 
based on two main lines of evidence: (1) the clearance 
of waste proteins requires protein folding machinery 
called chaperones [1], and (2) HSPs chaperones bind 
to denatured proteins to promote their degradation [2]. 
New evidence suggests that HSPs may actively 
participate in an array of cellular processes, including 
cytoprotection [3], and HSPs dysfunction may 
contribute to the pathogenesis of Parkinson’s disease 
(PD), a disease characterized by conformational 
changes in proteins that result in misfolding, 
aggregation and intracellular Lewy Body formation 
[4]. 
T h i s  r e v i e w  p r o v i d e s  a n  u p d a t e  v i e w  o f  t h e  
cytoprotective role of HSPs in PD and the potential 
therapeutic target of HSPs for the treatment of PD. 
2.  HSPs and PD Pathophysiology 
Many neurodegenerative disorders, including 
PD, Alzheimer’s disease (AD), amyotrophic lateral 
sclerosis (ALS), Huntington disease (HD) and other 
polyglutamine expansion disorders, are associated 
with degeneration and death of specific neuronal 
populations due to accumulation of certain abnormal 
polypeptides or proteins [4]. PD is a neurological 
disorder characterized by movement disturbance that 
mostly results from progressive degeneration of 
dopaminergic neurons in substantia nigra pars 
compacta (SNpc). Numerous studies implicate that at 
least two components of cellular proteins are 
associated with PD: the ubiquitin proteasomal system 
(UPS) and the HSPs [5, 6]. Transcriptional analysis of 
multiple brain regions in PD indicates the impairment 
of multiple electron transport chain complexes and 
the dysfunction of UPS in PD, along with a robust 
induction of several forms of HSPs [7]. Inclusion 
bodies called Lewy bodies with aberrant misfolding 
and aggregative proteins are common pathological 
hallmark in PD, indicating that abnormality of protein 
homeostasis may contribute to the pathogenesis of the 
disease [5]. Hsp70 and Torsin A, a homology to yeast 
Hsp104 and mutations of the gene causing dystonia, 
are colocalized with α-synuclein (αSN) containing 
Lewy bodies [8]. Further, Dedmon et al. [9] found that 
Hsp70 could inhibit αSN fibril formation through 
preferential binding to prefibrillar species to change 
the characteristics of toxic αSN aggregates. This work 
therefore elucidates a specific role of Hsp70 in the 
pathogenesis of PD and supports a general concept 
that chaperone action is a crucial aspect in protecting 
against the otherwise damaging consequences of 
protein misfolding [9]. With ageing, the level of HSPs 
is decreased insufficiently to keep the cellular proteins 
homeostasis, which may give rise to certain diseases Int. J. Biol. Sci. 2007, 3  21
[4, 5]. Since the proportion of patients suffering from 
PD in our aging society is increasing, it is urgent to 
find better therapeutic approaches to this devastating 
disease.  
3.  PD-Related Gene Mutations and Possible 
Association with HSPs 
During the last decade of discovery of several 
PD-associated mutant genes a remarkable progress 
has been made to help our understanding of the 
biology of PD. So far there are at least 6 genes and 
several loci that have been identified responsible to 
PD [10, 11]. It is hypothesized that UPS dysfunction 
resulted from these defected genes may cause protein 
misfolding and aggregation, and eventually lead to 
nigral cell degeneration [12]. Polymorphisms in the 5’ 
promoter regions of Hsp70 gene have been found 
significantly associated with PD [13].  
Alpha-synuclein (αSN)  
αSN, which plays a critical role in regulating 
synaptic vesicle size with particular relevance to 
dopamine storage, was found to be the main 
component in the Lewy body. Stress can increase the 
αSN protein aggregation and inclusion body 
formation [11, 14]; misfolding αSN can change 
proteasome composition, impair 
proteasome-mediated protein degradation, alter 
protein synthesis, and reduce the ability of cells to 
withstand stationary phase ageing [11, 15]. Three 
mutations of αSN, which show toxic gain-of-function, 
have been found in association with familial PD [10, 
11]. Inducible expression of mutant αSN in PC12 cell 
lines can result in greater sensitivity to proteasomal 
impairment, leading to mitochondrial abnormalities 
and neuronal cell death [16]. αSN at nanomolar 
concentration is able to increase Hsp70 protein level in 
PC12 cells, which can reduce αSN aggregation and 
toxicity [17]. In addition, the αSN protein has a 
tendency to self-aggregate and the protein level of 
αSN is increased in SNc with ageing [18]. 
Parkin  
Parkin is a member of E3 ligase in the UPS [19]. 
Parkin mutations are thought to result in the improper 
targeting of its substrates for proteasomal degradation 
leading to potentially neurotoxic accumulation [20]. 
Thus, great emphasis has been placed on the 
identification of substrates of parkin and their 
possible role in dopaminergic neuron loss in PD [11]. 
Kalia  et al showed that the bcl-2-associated 
athanogene 5 (BAG5) can enhance dopaminergic 
neuron death in a vivo model of PD through 
inhibiting the E3 ligase activity and the chaperone 
activity of Hsp70 [21].  
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) 
UCH-L1,  a highly abundant and neuronal 
specific protein that belongs to a family of 
deubiquitinating enzymes, is responsible for 
hydrolyzing polymeric ubiquitin chains to free 
ubiquitin monomers [10, 11]. UCH-L1 might 
additionally act as a dimerization-dependent 
ubiquitin protein ligase [22] and maintain ubiquitin 
homeostasis by promoting the stability of ubiquitin 
monomers in vivo [23]. When UCH-L1 mutates, 
ubiquitin recycling is reduced, which may lead to 
aggregation of aberrant proteins. It is found that 
UCH-L1 aggresomes colocalize with Hsp70, 
chaperone BiP, and other ubiquitinated proteins [24], 
suggesting that UCH-L1 may interact with HSPs in an 
attempt to participate in protein degradation.  
DJ-1  
DJ-1 is a novel oncogene and mutations in this 
gene can cause familial PD. It is repo rted that DJ-1 
mutations may result in oxidative stress and 
mitochondrial injury, which may lead to protein 
aggregation and neuronal cell death [10, 11]. Li et al 
[25] reported that DJ-1 and its mutants are associated 
with Hsp70, CHIP and mtHsp70/Grp75, a 
mitochondria-resident Hsp70; and DJ-1 and its 
mutants are colocalized with Hsp70 and CHIP in cells. 
Furthermore, H2O2 treatment in cells enhances DJ-1 
interaction with mtHsp70 in mitochondria [25]. These 
findings suggest that translocation of DJ-1 to 
mitochondria after oxidative stress is carried out by 
chaperones. 
4.  Protective Role of HSPs in PD 
It has been reported that Hsp70 is associated 
with  αSN, dopamine transporter (DAT), parkin, 
proteasome subunits, ubiquitin and UCH-L1 [18]. 
Hsp70 is believed not only to protect cells from 
rotenone-mediated cytotoxicity but also to decrease 
soluble  αSN aggregation [26]. Furthermore, Hsp70 
can work as a putative anti-apoptotic factor to protect 
against neuronal cell death in PD [3, 4]. These results 
highlight the possibility of using Hsp70 as a potential 
therapy for PD. Recent studies of function and inducer 
of Hsp90 also indicate its potential therapy for PD [27, 
28]. 
Hsp90  
Hsp90 is the main component of the cytosolic 
molecular chaperone complex that has been 
implicated in the negative regulation of the heat shock 
factor 1 (HSF1). HSF1 is responsible for the 
transcriptional activation of the heat shock genes 
including Hsp40, Hsp70, and Hsp90 [29], suggesting a 
regulatory role in Hsp90 synthesis at the 
transcriptional level. Hsp90 forms a multichaperone 
complex with Hsp70 and Hsp40 to regulate several 
regulatory proteins, such as steroid hormone 
receptors [30] and transcription factors [31], and to 
modulate the protein translocation from peroxisomal 
to organelle [32]. The interplay between these 
chaperones is of crucial importance for cell function 
and survival. Recently, Uryu et al. demonstrated that 
Hsp90 was predominantly increased in PD brains, 
which was in correlation with the elevated level of 
insoluble αSN. These alterations of Hsp90 in PD brain 
were recapitulated by neuropathological findings in 
αSN mutant transgenic mouse model of PD [27]. 
Furthermore, exposure of cells to proteasome 
inhibitors resulted in increased levels of Hsp90 [27].  
Microglia, which plays a principal role of 
inflammation in brain [33], express high levels of 
Hsp90 following excitotoxic lesion in the mouse 
hippocampus [34]. The protective function of Hsp90 
can be very important since inflammation evoked by 
microglia may increase the risk of PD. Recently, we 
have demonstrated that (-)-Epigallocatechin gallate 
EGCG, a major monomer of green tea polyphenols, is Int. J. Biol. Sci. 2007, 3  22
a potent inhibitor of microglial activation [35]. EGCG 
could directly bind to Hsp90 and stabilize the complex 
of Hsp90 [36]. Thus EGCG could be used to alleviate 
microglia-mediated dopaminergic neuronal injury in 
PD. 
Hsp70 
Auluck  et al. [37] reported that application of 
Hsp70 can prevent dopaminergic neuronal loss in 
αSN transgenic Drosophila and interference with 
endogenous chaperone activity can accelerate αSN 
toxicity. Furthermore, Lewy bodies in human 
postmortem tissues were usually immunostained 
positive for molecular chaperones, suggesting that 
chaperones may play a role in PD progression [37].  
It has been reported that Hsp70 can enhance 
parkin binding and ubiquitinating of expanded 
polyglutamine protein in vitro, suggesting that Hsp70 
may help recruit misfolded proteins as substrates for 
parkin E3 ubiquitin ligase activity [38]. This finding 
provides a direct evidence to show the Hsp70 can 
promote the activity of E3 ligase to degrade aberrant 
αSN. 
It is postulated that Hsp70 itself or cooperating 
with other factors can protect the neurons from 
cytotoxicity caused by aberrant proteins. The crosstalk 
between the Hsp70 and UPS may provide a clue for 
the intrinsic mechanism of protein aggregation and 
degradation. Moreover, Hsp70 exerts anti-apoptotic 
activity by blocking the function of several key 
proapoptotic factors [3]. Recently, several studies have 
demonstrated that Hsp70 may play a role in 
neuroprotection against rotenone-mediated apoptosis 
in human dopaminergic cell line SH-SY5Y in vitro and 
against MPTP-induced nigral injury in vivo by 
inhibiting the proapoptotic factors as well as 
activating the survival pathway [39, 40].  
Small HSPs 
Chaperone Hsp25/27(Hsp25 in mice and Hsp27 in 
humans), is an inhibitor of actin polymerization [41], 
which has been demonstrated to play a major role in 
actin filament dynamics in diverse cell types [3].  
In human endothelial cells, inhibition of 
p38-MAPK activation can abolish Hsp27 
phosphorylation, actin polymerization, and cell 
migration [42]. p38-MAPK may act as an upstream 
activator of stress-inducible Hsp25/27 
phosphorylation. It has been demonstrated that 
Hsp27 could bind to the microtubule associated 
protein tau and lead to decreased level of 
hyperphosphorylated tau and therefore enhance cell 
survival in AD [43]. Another important function of 
Hsp27 is its protective effects on mitochondria 
pathway leading to inhibition of apoptosis [44]. It has 
been found that Hsp27 can block the tBID entering the 
mitochondria and reduce SMAC and Cytochrome C 
releasing from mitochondria so as to block the 
apoptotic process [3].  
αB-crystallin Chaperone (Hsp22): Increased 
expression and abnormal aggregation of small HSPs 
αB-crystallin has been detected in Lewy bodies and 
reactive astrocytes in various neurodegenerative 
diseases [45]. Rekas et al. demonstrated that 
αB-crystallin was a potent inhibitor of αSN 
fibrillization  in vitro [46]. αB-crystallin may redirect 
αSN from a fibril-formation pathway towards an 
amorphous aggregation pathway, thus reducing the 
amount of physiologically stable amyloid deposits in 
favor of easily degradable amorphous aggregates [46]. 
It has been reported that treatment with proteasomal 
inhibitors MG-132 or lactacystin in cultured rat brain 
oligodendrocytes can cause apoptotic cell death and 
induction of heat shock proteins in a time- and 
concentration-dependent manner [47]. Specifically in 
this study, αB-crystallin was up-regulated, and 
ubiquitinated proteins were accumulated. Meanwhile, 
the tau was dephosphorylated, which enhanced its 
microtubule-binding capacity [47]. These findings 
imply that αB-crystallin may work together with other 
HSPs, ubiquitin and microtubule associated proteins 
(MAPs) to cope with stressed conditions. 
5.  Potential Target for the Treatment of PD 
Dong  et al. [48] reported that Hsp70 gene 
transferred to dopaminergic neurons by a 
recombinant adeno-associated virus significantly 
protected the mouse against MPTP-induced nigral 
dopaminergic neuron loss and striatal dopamine 
levels decline [48]. Hsp70 attenuated MPTP induced 
apoptosis in the SNpc, and increased 
amphetamine-induced rotation [48]. Collectively, 
these results demonstrate that increasing chaperone 
activity may be beneficial for the treatment of PD.  
HSPs may exert protective function through two 
major pathways besides their own chaperon activity: 
reducing mitochondrial dysfunction and oxidative 
stress, and preventing UPS impairment.  
Anti-apoptotic effects of HSPs in PD 
Mitochondrial dysfunction is probably the 
leading cause of increased oxidative stress and 
apoptosis in PD. Dopaminergic neurons are more 
vulnerable to oxidative stress than other neurons 
because of the special substrate dopamine [49]. In 
general, apoptotic process can be divided into the 
three phases: induction (or triggering), transduction of 
signal, and execution. Theoretically, HSPs may 
modulate any of these apoptotic phases to rescue the 
c e l l s  [ 3 ,  5 0 ] .  I n  a d d i t i o n ,  i t  h a s  b e e n  r e p o r t e d  t h a t  
stable expression of wild-type αB-crystallin protects 
cancer cells from caspase-3 activation in vitro, 
indicating that small HSPs αB-crystallin is a novel 
inhibitor of the activation of apoptosis [51]. (Figure 1) 
Other gene products linked to monogenic forms of PD 
also appear to be implicated in mitochondrial 
dysfunction. Parkin can interact with leucine-rich 
repeat kinase 2 (Lrrk2) which is part of the 
mitochondrial outer membrane [52, 53]. Thus Parkin 
may have an unexpected role in the regulation of 
normal mitochondrial function in an indirect way [54, 
55].  
HSPs may promote the UPS in protein degradation  
The UPS plays a pivotal role in the degradation 
of short-lived regulatory proteins which are 
components of cell cycle regulation, cell surface 
receptors, ion channels modulation, and antigen 
presentation [56]. (Figure 2) It is believed that once the 
disposal system fails to work, the substances, such as 
regulatory molecules p53, NFκB, and Bax that 
promote apoptosis, may accumulate to a high level 
that is harmful to the cell [57]. A hypothesis for the Int. J. Biol. Sci. 2007, 3  23
etiology of PD is that subsets of neurons are 
vulnerable to a failure in proteasome-mediated 
protein turnover [56]. Accumulation of ubiquitin 
conjugates has been reported in the pathologic lesions 
of many chronic neurodegenerative diseases, such as 
the neurofibrillary tangles in AD and brainstem Lewy 
bodies in PD [55, 56]. Inhibition of proteasome activity 
will sensitize dopaminergic neurons to protein 
alterations and oxidative stress [58]. 
Hsp90, together with Hsc70, Hsp40 and 20S 
proteasome subunit are the effective components to 
capture firefly luciferase during thermal inactiveness 
and to prevent it from undergoing an irreversible 
off-pathway [59]. The 20S proteasome has been found 
in tight association with the molecular chaperone 
Hsp90 [60]. Composed within 26S proteasome subunit, 
they form a complex involved in a multitude of 
intracellular processes [56]. In addition, Kim et al has 
demonstrated that the inhibition of proteasome can 
increase the expression of Hsp27 and Hsp70 [61], 
implying that HSPs may act as compensation of UPS 
or work together to regulate the intracellular protein 
level. Robertson et al. supported the hypothesis by 
demonstrating that Hsp70 antisense oligomers 
enhanced proteasome inhibitor-induced apoptosis 
[62].  
All evidences above implicate that HSPs and 
UPS are participants in keeping proteins folding 
correctly. They provide an effective protein quality 
control system that is essential for cellular functions 
and survival in many tissues. Dysfunction of these 
systems leads to protein aggregation and inclusion 
body formation in dopaminergic neurons.  
Figure 1: The role of anti-apoptosis of families of HSPs. Most of them function as the inhibitor of the crucial molecule in the 
apoptosis pathway such as JNK, BAK, Cyto C, caspase-3 and et al. Meanwhile, Hsp27 and Hsp90 can also promote function 
of AKT to maintain the cell survival. 
 Int. J. Biol. Sci. 2007, 3  24
Figure 2: The Ubiquitin-Proteasome System and the functions of PD associated genes. Parkin works as E3 ligase to help the 
aberrant protein be poly-ubiquitinated. And UCH-L1 helps hydrolyze the poly-Ub to Ub which can be reused in the next 
cycle. And when the 26S proteasome is inhibited, HSPs will be induced to compensate the function of protein degradation. 
 
 
HSPs inducers and their potential application in PD 
It is proposed that up-regulation of protective 
factors may benefit our cells, but overload of some 
proteins may be a burden for cells or even cause 
cancer. So we need to find better way to keep cells in 
delicate balance with maximal protective effects and 
minimal side effects.  
Cyclopentenone prostaglandin A1 (PGA1), an 
inducer of HSPs, has been shown to inhibit SH-SY5Y 
neuron apoptosis. PGA1 can protect against 
rotenone-induced neuronal degeneration by 
promoting the expression of HSPs as well as 
attenuating nuclear translocation of NF-kappaB and 
caspase-3 activation [63].  
Geldanamycin (GA) binds to an ATP site on 
HSP90 and blocks its interaction with HSF1 to 
promote HSF1 activation [64]. GA also sensitizes the 
stress response within normal physiological 
parameters to enhance chaperone activation and offer 
protection against αSN neurotoxicity [65]. 
Furthermore, GA uncouples neuronal toxicity from 
Lewy body and Lewy neurite formation so that 
dopaminergic neurons are protected from the effects 
of αSN expression despite the continued presence of 
or even increased inclusion pathology [65]. 
Significantly, GA does not alter the basal level of 
HSP70, suggesting that GA acts only to elevate 
chaperone levels in stressed cells and does not alter 
chaperone activity in neighboring, healthier cells [65]. 
Because αSN expression leads to a local elevation of 
inducible HSP70 in dopaminergic neurons [37], these 
neurons should be preferentially targeted by GA 
treatment [65]. Its new derivative 
17-Allylamino-17-demethoxygeldanamycin 17-AAG 
shares its important biological activities with less 
toxicity [28], which gives us a much bright perspective 
to use GA to induce specific HSPs expression and to 
attenuate the side effect.  
There is feasibility to use Hsp70 as a 
pretreatment therapy because there are many 
nontoxic or low toxic Hsp70 inducers available, such 
as paeoniflorin [66], bimoclomol (co-inducer to 
increase the activity) [67, 68], radicicol, and valproic 
acid (VPA) [39]. These Hsp70 inducers can 
up-regulate Hsp70 effectively for reconfirmation of 
the cellular homeostasis. Thus, it is hope that 
modulates the stress response by inducers can be a 
promising target for treatment of PD.  Int. J. Biol. Sci. 2007, 3  25
6.  Conclusion 
HSPs have two main cellular functions aimed at 
promoting the UPS function and inhibiting the 
apoptotic activity. However, the detailed molecular 
mechanisms underlying their biological functions are 
still unclear. It is believed that HSPs, UPS, 
mitochondria and other organelles may work 
coordinately to keep the cell in a stable and 
well-operated state. HSPs are particularly important 
in PD and other neurodegenerative disorders because 
aberrant protein aggregation and neuron 
degeneration are the common pathophysiology of 
these disorders. Numerous studies in vitro and in vivo 
model of PD have demonstrated that increase in the 
expression of HSPs especially Hsp70 by gene transfer 
or HSPs inducers can reduce the aberrant protein 
misfolding and inhibit the proapoptotic pathway to 
attenuate dopaminergic neuron degeneration. Thus 
such intervention provides a promising therapy for 
PD. Advance in the research of HSPs targets will shed 
a light on the feasibility of clinical application of HSPs 
in PD. The future study will focus on finding the 
mechanisms of aberrant protein aggregation and 
searching for the selective HSPs inducers for the 
treatment of PD. 
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